The present study demonstrated that the presence of brain metastasis in EGFR-mutant NSCLC patients had clinical impact on the efficacy of front-line EGFR-TKI treatment, particularly for the first-generation one; whereas the impact toward OS was not significant. This evidence concerns the gene EGFR and non-small cell lung carcinoma.